

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.*

*This announcement is not, and does not form any part of, an offer or invitation for the sale of securities in the United States or to, or for the account or benefit of any U.S. person (as defined in Regulation S under the Securities Act). The securities referred to herein have not been and will not be registered under the Securities Act, and may not be offered, sold or otherwise transferred within the “United States” or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act) unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. There will be no public offer of securities in the United States. No money, securities or other consideration is being solicited by this announcement or the information contained herein.*

**Sisram Medical Ltd**  
**復銳醫療科技有限公司\***  
*(Incorporated in Israel with limited liability)*  
**(Stock Code: 1696)**

**COMPLETION OF PLACING OF NEW SHARES UNDER THE  
ISSUANCE MANDATE**

**Joint Bookrunners and Placing Agents**



Reference is made to the announcement of Sisram Medical Ltd (the “**Company**”) dated 20 July 2021 (the “**Placing Announcement**”) in relation to the placing of 24,000,000 new Shares of the Company (the “**Placing**”). Unless otherwise defined, all capitalized terms used herein shall have the same meanings as defined in the Placing Announcement.

**COMPLETION OF THE PLACING**

The Board is pleased to announce that all conditions precedent to the Placing, as set out in the Placing Agreement, have been satisfied, and completion of the Placing took place on 27 July 2021 (the “**Completion**”). A total of 24,000,000 new Shares, representing approximately 5.15% of the total issued share capital of the Company as enlarged by the allotment and issue of the Placing Shares, have been placed to no less than six Placees who, to the best of the knowledge, information and belief of the Directors, are third parties independent of the Company. Please refer to the Placing Announcement for further details of the Placing.

## CHANGE IN SHARE CAPITAL UPON COMPLETION OF THE PLACING

The number of total issued Shares of the Company has increased from 442,155,600 Shares to 466,155,600 Shares as a result of the issue of the Placing Shares. The share capital of the Company immediately following the Completion is as follows:

<b>Name</b>	<b>No. of Shares</b>	<b>Approximate percentage of issued share capital</b>
Ample Up <sup>(1) (2)</sup>	203,240,160	43.60%
CML	127,318,640	27.31%
Other Shareholders	135,596,800	29.09%
<b>Total</b>	<b>466,155,600</b>	<b>100.00%</b>

*Notes:*

- (1) As at the date of this announcement, CML is wholly-owned by Ample Up, which in turn is wholly-owned by Fosun Pharma.
- (2) These only represent the Shares beneficially owned by Ample Up, and do not include the Shares deemed to be interested by Ample Up by virtue of its shareholding in CML.

On behalf of the Board  
**Sisram Medical Ltd**  
復銳醫療科技有限公司\*  
**Yi LIU**  
*Chairman*

Hong Kong, 27 July 2021

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as Executive Directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-Executive Directors.*

\* for identification purpose only